U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

peginterferon alfa-2b response - Efficacy

MedGen UID:
1002137
•Concept ID:
CN322748
•
Sign or Symptom

Professional guidelines

PubMed

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á, Pinczés LI, Egyed M
Expert Opin Drug Metab Toxicol 2021 Jan;17(1):3-7. Epub 2020 Oct 29 doi: 10.1080/17425255.2021.1839050. PMID: 33118413
Novel treatment strategies for myeloproliferative neoplasms.
Bose P, Masarova L, Verstovsek S
Rinsho Ketsueki 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. PMID: 31597841
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Noureddin M, Ghany MG
Gastroenterol Clin North Am 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. PMID: 20951922Free PMC Article

Recent clinical studies

Etiology

Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, Liao J, Lin S, Chang C, Chen H, Cui J, Su X
Br J Clin Pharmacol 2024 Jun;90(6):1493-1502. Epub 2024 Mar 19 doi: 10.1111/bcp.16043. PMID: 38500445
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A
Lancet Haematol 2021 Mar;8(3):e175-e184. Epub 2021 Jan 18 doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á, Pinczés LI, Egyed M
Expert Opin Drug Metab Toxicol 2021 Jan;17(1):3-7. Epub 2020 Oct 29 doi: 10.1080/17425255.2021.1839050. PMID: 33118413
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group
Lancet Haematol 2020 Mar;7(3):e196-e208. Epub 2020 Jan 31 doi: 10.1016/S2352-3026(19)30236-4. PMID: 32014125
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S
Lancet Haematol 2020 Mar;7(3):e226-e237. Epub 2020 Jan 23 doi: 10.1016/S2352-3026(19)30207-8. PMID: 31982039Free PMC Article

Diagnosis

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A
Lancet Haematol 2021 Mar;8(3):e175-e184. Epub 2021 Jan 18 doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group
Lancet Haematol 2020 Mar;7(3):e196-e208. Epub 2020 Jan 31 doi: 10.1016/S2352-3026(19)30236-4. PMID: 32014125
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S
Lancet Haematol 2020 Mar;7(3):e226-e237. Epub 2020 Jan 23 doi: 10.1016/S2352-3026(19)30207-8. PMID: 31982039Free PMC Article
Impact of therapy on the outcome of chronic hepatitis B.
Liaw YF
Liver Int 2013 Feb;33 Suppl 1:111-5. doi: 10.1111/liv.12057. PMID: 23286854
Improving anti-hepatitis C virus therapy.
Pol S, Mallet VO
Expert Opin Biol Ther 2006 Sep;6(9):923-33. doi: 10.1517/14712598.6.9.923. PMID: 16918259

Therapy

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A
Lancet Haematol 2021 Mar;8(3):e175-e184. Epub 2021 Jan 18 doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group
Lancet Haematol 2020 Mar;7(3):e196-e208. Epub 2020 Jan 31 doi: 10.1016/S2352-3026(19)30236-4. PMID: 32014125
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S
Lancet Haematol 2020 Mar;7(3):e226-e237. Epub 2020 Jan 23 doi: 10.1016/S2352-3026(19)30207-8. PMID: 31982039Free PMC Article
Novel treatment strategies for myeloproliferative neoplasms.
Bose P, Masarova L, Verstovsek S
Rinsho Ketsueki 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. PMID: 31597841
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Noureddin M, Ghany MG
Gastroenterol Clin North Am 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. PMID: 20951922Free PMC Article

Prognosis

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á, Pinczés LI, Egyed M
Expert Opin Drug Metab Toxicol 2021 Jan;17(1):3-7. Epub 2020 Oct 29 doi: 10.1080/17425255.2021.1839050. PMID: 33118413
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group
Lancet Haematol 2020 Mar;7(3):e196-e208. Epub 2020 Jan 31 doi: 10.1016/S2352-3026(19)30236-4. PMID: 32014125
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S
Lancet Haematol 2020 Mar;7(3):e226-e237. Epub 2020 Jan 23 doi: 10.1016/S2352-3026(19)30207-8. PMID: 31982039Free PMC Article
Interferon Alpha 2a and 2b in Ophthalmology: A Review.
Lewczuk N, Zdebik A, Bogusławska J
J Interferon Cytokine Res 2019 May;39(5):259-272. Epub 2019 Apr 5 doi: 10.1089/jir.2018.0125. PMID: 30950678
Boceprevir.
Prescrire Int 2012 Apr;21(126):89-92. PMID: 22515132

Clinical prediction guides

Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, Liao J, Lin S, Chang C, Chen H, Cui J, Su X
Br J Clin Pharmacol 2024 Jun;90(6):1493-1502. Epub 2024 Mar 19 doi: 10.1111/bcp.16043. PMID: 38500445
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A
Lancet Haematol 2021 Mar;8(3):e175-e184. Epub 2021 Jan 18 doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S
Lancet Haematol 2020 Mar;7(3):e226-e237. Epub 2020 Jan 23 doi: 10.1016/S2352-3026(19)30207-8. PMID: 31982039Free PMC Article
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L
Clin Res Hepatol Gastroenterol 2014 Sep;38(4):440-50. Epub 2013 Oct 28 doi: 10.1016/j.clinre.2013.08.013. PMID: 24176812
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000. PMID: 20108989

Recent systematic reviews

Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM, Gevers TJ, Drenth JP
J Viral Hepat 2015 Dec;22(12):965-73. Epub 2015 Mar 11 doi: 10.1111/jvh.12403. PMID: 25760481
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L
Clin Res Hepatol Gastroenterol 2014 Sep;38(4):440-50. Epub 2013 Oct 28 doi: 10.1016/j.clinre.2013.08.013. PMID: 24176812
Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G
HIV Clin Trials 2013 Jul-Aug;14(4):127-39. doi: 10.1310/hct1404-127. PMID: 23924585
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
Singal AK, Jampana SC, Anand BS
Dig Dis Sci 2011 Aug;56(8):2221-6. Epub 2011 Jun 4 doi: 10.1007/s10620-011-1765-0. PMID: 21643737
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D, Jones J, Baxter L, Shepherd J
Health Technol Assess 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. PMID: 21473834Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...